http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Dibbendhu Khanra,Anindya Mukherjee,Saurabh Deshpande,Hassan Khan,Sanjeev Kathuria,Danesh Kella,Deepak Padmanabhan 대한골대사학회 2021 대한골대사학회지 Vol.28 No.2
Background: There are limited studies comparing the risk of osteoporosis and fractures between different direct oral anticoagulants (DOACs) and vitamin K antagonists (VKA) in non-valvular atrial fibrillation (AF). Using a network meta-analysis (NMA), we compared osteoporotic fractures among 5 different treatment arms, viz. dabigatran, rivaroxaban, apixaban, edoxaban, and VKA. Methods: Ten studies, including 5 randomized control trials and 5 population-based studies, with a total of 321,844 patients (148,751 and 173,093 in the VKA and DOAC group, respectively) with a median follow-up of 2 years, were included. A Bayesian random-effects NMA model comparing fractures among the treatment arms was performed using MetInsight V3. Sensitivity analysis excluded studies with the highest residual deviances from the NMA model. Results: The mean age of the patients was 70 years. The meta-analysis favored DOACs over VKA with significantly lower osteoporotic fracture (odds ratio [OR], 0.77; 95% credible interval [CrI], 0.70-0.86). The NMA demonstrated that fractures were significantly lower with apixaban compared with dabigatran (OR, 0.64; 95% CrI, 0.44-0.95); however, fractures were statistically similar between apixaban and rivaroxaban (OR, 0.84; 95% CrI, 0.58-1.24) and dabigatran and rivaroxaban (OR, 1.32; 95% CrI, 0.90-1.87). Based on the Bayesian model of NMA, the probability of osteoporotic fracture was highest with VKA and lowest with apixaban, followed by rivaroxaban, edoxaban, and dabigatran. Conclusions: The decision to prescribe anticoagulants in elderly patients with AF should be made not only based on thrombotic and bleeding risks but also on the risk of osteoporotic fracture; these factors should be considered and incorporated in contemporary cardiology practice.
Radiolucent implantable electrocardiographic monitoring device based on graphene
Bong, Jihye,Attia, Zachi I.,Vaidya, Vaibhav R.,Jung, Yei Hwan,Padmanabhan, Deepak,Lee, Juhwan,Kim, Hyungsoo,Ladewig, Dorothy J.,Noseworthy, Peter A.,Asirvatham, Samuel J.,Park, Dong-Wook,Friedman, Pau Elsevier 2019 Carbon Vol.152 No.-
<P><B>Abstract</B></P> <P>Conventional implantable electrocardiogram monitors are impenetrable to electromagnetic radiation, posing challenges in imaging (i.e. X-rays). In this study, we demonstrate a radiolucent implantable electrocardiogram (ECG) device using graphene sheets and Parylene substrate which allows bypassing of electromagnetic radiation through the implanted device. Evaluated on a canine model, the graphene electrodes detect signals comparable to those recorded using surface electrodes, presenting a valuable and novel modality for medium and long-term monitoring of cardiac rhythm. When compared with current technology, the new system has the distinct advantages of being flexible and radiolucent, thereby improving patient comfort, and avoiding device artifact and shadowing on clinical radiographic imaging.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>